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www.cdatm.orgAbstractObjectives: To describe the extent to which irritable bowel syndrome (IBS), fibromyalgia syndrome (FMS), and chronic fatigue
syndrome (CFS) exhibit symptom overlap, and to validate a patient-derived, generic symptom questionnaire.
Methods: A patient-derived 61-item symptom-frequency questionnaire was completed by participants recruited through IBS,
FMS and CFS self-help websites. Principal axis factor analysis with oblimin rotation was performed separately for those reporting
an IBS, FMS or CFS diagnosis.
Results: Questionnaires were completed by 1751 participants of whom 851 reported more than one of the three diagnoses.
Stomach pain on at least a weekly basis was reported by 79% of IBS, 52% of FMS, and 43% of CFS single diagnosis participants.
Pain increasing the day after activity was reported by 32% of IBS, 94% of FMS, and 85% of CFS single diagnosis participants.
Waking still tired at least once weekly was reported by 75% of IBS, 97% of FMS, and 95% of CFS single diagnosis participants.
Exploratory factor analysis produced consistent results across all three diagnostic groups, the 61 items loading on 12 correlated
factors with a single higher order factor on which all items loaded. Frequency analysis led to the rejection of one item (cold sores on
or near lips), and freeform reporting by participants of additional symptoms identified an additional five, namely, restless legs, hair
loss/brittle hair/thinning, dizziness/balance problems, blurred vision and urination problems.
Conclusions: IBS, FMS and CFS are polysymptomatic spectrum disorders with a wide range of overlapping symptoms, many of
which are unrelated to diagnostic criteria. Frequency analysis and factor analysis confirm the validity of using the same ques-
tionnaire across different diagnostic categories. The 65-item general symptom questionnaire (GSQ-65) is a valid generic symptom
scale suitable for assessing the many different symptoms of people with IBS, FMS and CFS.
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Functional disorders are diagnosed by symptoms
after other biomedical causes of these symptoms are
ruled out. Three common functional disorders are ir-
ritable bowel syndrome (IBS), fibromyalgia syndrome
(FMS) and chronic fatigue syndrome (CFS), with
prevalence (but varying with population diagnostic
criteria) of approximately 10%, 2.5% and 0.2%,
respectively.1e3 Each of these different functional
disorders is diagnosed by a different set of symptoms,
and symptom specific scales exist to assess outcome in
intervention studies.4e7
Research shows that there is considerable comor-
bidity between the different functional disorders, and
that patients with one functional disorder have a higher
probability of having symptoms characteristic of other
functional disorders.8e14 Whether or not functional
disorders should be classified as separate (“splitters”)
or not (“lumpers”), there is consensus that functional
disorders should be considered, at least to some extent,
spectrum disorders, and that patients with any classi-
fication are polysymptomatic.15
If functional disorders are spectrum disorders and
polysymptomatic, then scales that are designed to
measure the symptoms of one particular functional
disorder may not provide a comprehensive picture of
the patient's symptoms. A comprehensive, generic
functional disorder measure of symptoms is useful in
outcome studies because interventions for functional
disorders (e.g., psychological interventions and exer-
cise regimens) can have a range of benefits that may
not be measured in a disorder specific scale.
The Composite Autonomic Symptom Score
(COMPASS) is a commonly used generic scale for
functional disorders. The COMPASS consists of 84
symptoms selected from the 169-symptom autonomic
symptom profile (ASP).16 A shorter 31-item version of
the COMPASS, the COMPASS 31 scale, has also been
published.17 Although the COMPASS is valid as a
generic functional disorder scale, it is not simple to
score and has not been optimised for the three func-
tional disorders that are the focus of this study, namely,
IBS, FMS, and CFS, and where optimisation includes
sensitivity to change in clinical trials.
There are three aspects to optimising a generic
symptom scale for use in intervention studies of IBS,
FMS or CFS. First, comprehensiveness can beachieved only by including symptoms that are experi-
enced by a subset of the total population. However, if
the proportion of people within a population experi-
encing that symptom is very low, then there will be
little possibility for improvement. Symptoms that are
not experienced cannot improve, nor can symptoms
that always occur. Although floor and ceiling effects
should be avoided, sensitivity to change (and cross-
sectional discrimination) over the full range of sever-
ities requires a questionnaire made up of symptoms
with varying degrees of frequency. A scale that is
sensitive to change in more severe patients requires
symptoms that are comparatively infrequent, whereas a
scale that is to be sensitive to change for mild patients
requires symptoms that are comparatively frequent.
Thus, in order to select symptoms for inclusion in a
scale, it is necessary to identify prevalence and distri-
bution of responses.
Second, there are some symptoms that are highly
indicative of particular functional disorders, and it is
important that these indicative symptoms should be
included. For example, in FMS a common symptom is
the experience of pain shifting from one part of the
body to another. Shifting pain is unlikely to be caused
by peripheral damage and can be an indicator of the
centralised pain of FMS. Similarly, CFS patients report
that they feel extremely tired the day after increased
activity. The “boom and bust” phenomenon of over and
under activity is a clinical feature of some patients.
Thus, a generic functional disorder symptom scale for
IBS, FMS and CFS requires some items that are spe-
cific to these disorders, and expressed in the language
of patients with these disorders.
Finally, questionnaires are susceptible to anchoring
effects,18,19 also known as response shift.20 As they
improve, patients can change their perceptions of the
two end points of a scale (the anchors), and this change
in “anchoring” or “response shift” then leads to an
underestimation of real change. Symptom scales with
severity response scales (e.g., mild, severe) or with
non-numeric frequency response scales (e.g., seldom,
often) are subject to response shift. Symptom scales
with numeric frequency response scales (e.g., once a
week, once a day) are less susceptible, and will
therefore reduce the impact of response shift.
The aims of this paper were to examine the symp-
tomatology of people with IBS, FMS and CFS to
determine to what extent they are spectrum disorders,
131M.E. Hyland et al. / Chronic Diseases and Translational Medicine 5 (2019) 129e138and on the basis of that evidence to produce a generic
functional disorder questionnaire suitable for patients
with a diagnosis of IBS, FMS, and CFS, that (a) is easy
to score and produces a single, valid score, (b) uses a
numeric frequency response rating scale, (c) uses lan-
guage adopted by patients and has a single simple
response format and (d) is based on the frequency of
symptoms in this population so that the final scale
comprises symptoms with a range of frequencies.
Methods
Initial questionnaire construction
An initial symptom questionnaire was constructed
by comparing and selecting items from a variety of
sources including questionnaires designed for the
general population7,21,22 using the numeric response
scale of one of these scales,21 adding symptoms that
are clinical features of IBS, FMS and CFS so as to
produce a 59-item questionnaire. The 59-symptom
questionnaire was completed by thirteen non-
epileptic seizure patients attending a neurology
clinic as part of a separate study21 and twenty-five
FMS patients attending a rehabilitation course as part
of a separate study.22 Patients were encouraged to
identify additional symptoms and to suggest ways in
which the wording of the symptoms could be
improved. Additionally, a group of physically active
healthy people commented on the 59-symptom
questionnaire and suggested changes to avoid ambi-
guity (e.g., pain or fatigue that had a lifestyle based
explanation). These various forms of feedback led to
modifications to produce the 61-symptom question-
naire used in this study. Modifications included
changes or expansions to symptom descriptors to
improve clarity and avoid ambiguity as well as adding
additional symptoms (e.g., double vision). The list of
symptoms includes many that are used in other ques-
tionnaires, but also some that are unique.
For each symptom, respondents had 6 response
options (value of response for scoring shown in
parenthesis): never or almost never (1), less than 3 or 4
times per year (2), every month or so (3), every week
or so (4), more than once per week (5), every day (6).
Data collection
Questionnaire completion was advertised on web-
sites of IBS, FMS and CFS and IBS self-help groups in
the UK and Canada. The advertisements directed par-
ticipants to a website that provided information aboutthe study and where patients provided a positive
response to show that they had understood and were
willing to take part. After providing online consent by
clicking the consent box, participants were asked to
indicate which of the following three diagnoses they
had been given “by a doctor” (any combination was
allowed, but patients were required to select at least
one). Participants then viewed the list of symptoms and
responded to each symptom with one of the six
response options. At the end of the questionnaire, there
was a textbox in which participants were able to write
“any other symptom”. Ethical approval for the study
was given by the University of Plymouth, Faculty of
Health and Social Science human participants ethical
committee.
Statistical analysis
In order to determine to what extent patients were
polysymptomatic, respondents were allocated to one of
seven groups: IBS-only, FMS-only, CFS-only,
IBS þ CFS, CFS þ FMS, IBS þ FMS, and
IBS þ CFS þ FMS. The 61-symptom questionnaire
was scored in three ways. The number of symptoms
experienced on at least a weekly basis was calculated
by counting the number of symptoms with values 4 or
above to give the weekly symptom score. The number
of symptoms experienced every day was calculated by
counting the number of symptoms with value 6 to give
the daily symptom score. A symptom scale score was
calculated by taking the average score (1e6) of all 61
symptoms.
Differences between the seven groups were tested
with one-way analysis of variance for data distrib-
uted normally followed by paired comparison using
the Scheffe test. F values were used to compare
between different scoring methods. A P value <0.05
was considered statistically significant. Exploratory
factor analysis was used to compare the factor
structures of different groups. For this analysis, re-
spondents were allocated to one of three groups if
they reported an IBS, FMS or CFS diagnosis irre-
spective of other diagnoses, these groups being
labelled any-IBS, any-FMS and any-CFS (i.e., the
any-IBS group includes the IBS-only, IBS þ CFS,
IBS þ FMS and IBS þ CFS þ FMS groups).
Separate exploratory factor analysis for each of the
any-IBS, any-FMS and any-CFS groups was carried
out with principal axis factor extraction and oblimin
rotation using the scree and KaisereGuttman tests to
inform factor number and checking for consistency
across populations following recommended, theory
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significant loading was 0.3. Symptoms loading <0.3
were assumed to contribute insufficient variance to
the latent variable, either because variance is
attributable to another latent variable or because of
attenuation of range due to floor or ceiling effects.
Any symptom with a frequency of <10% both for
the total population and in any one of the three
groups, IBS, CFS and FMS, was defined as too
infrequent for inclusion in any final questionnaire.
Cronbach's alpha coefficient was calculated for the
total population.
Results
Completed questionnaires were received from 1751
respondents (1592 female, mean age 50 ± 13 years,
range 16e88 years). The numbers of participants in
each of the groups were IBS-only (370), FMS-only
(384), CFS-only (146), IBS þ CFS (108),
FMS þ CFS (99), IBS þ FMS (378), and
IBS þ FMS þ CFS (266). There was a significant
difference (P < 0.001) between groups for each of the
three scoring methods; for the daily symptom score
F ¼ 104.3, for the weekly symptom score F ¼ 141.9,
and for the symptom scale score F ¼ 155.1.
For the symptom scale score, the means (standard
deviation [SD]) are IBS ¼ 2.81 (0.78), CFS ¼ 3.46
(0.72), CFS þ IBS ¼ 3.65 (0.84), FMS ¼ 3.67 (0.76),
FMS þ CFS ¼ 3.96 (0.63), IBS þ FMS ¼ 4.06 (0.71),
and IBS þ FMS þ CFS ¼ 4.29 (0.75). Paired compar-
ison using the Scheffe test showed that only the first two
and last two adjacent pairs of this sequence were
significantly different (Table S1 in the Supplementary
Appendix). All other comparisons were significantly
different except for IBSþ CFS versus CFSþ FMS. For
the daily symptom score, themeans are IBS¼ 6.95 (7.4),
CFS ¼ 13.29 (7.7), IBS þ CFS ¼ 15.61 (9.8),
FMS ¼ 16.16 (9.0), FMS þ CFS ¼ 18.96 (8.6),
IBS þ FMS ¼ 19.64 (10.2), and
IBS þ CFS þ FMS ¼ 23.60 (19.5). The results from
paired comparisons for the daily symptom scores are the
same as those for the symptom scale score with the
exception that the pair of CFS and FMS were not
significantly different (Table S2 in the Supplementary
Appendix). The weekly symptom scores are
IBS ¼ 21.89 (11.7), CFS ¼ 31.60 (10.7),
IBS þ CFS ¼ 34.05 (12.7), FMS¼35.25 (10.9),
CFS þ FMS ¼ 38.12 (9.1), IBS þ FMS ¼ 40.94 (9.8),
and IBSþ CFSþ FMS¼ 43.56 (10.4). The results from
the paired comparison showed that only the first adjacent
pair in this sequence were significantly different. Allother non-adjacent comparisons were significantly
different (Table S3 in the Supplementary Appendix).
The number of symptoms reported on a daily or at
least weekly basis as a function of each of the seven
groups is shown in Table 1. Although the number of
symptoms increases as the number of diagnoses in-
creases, there is a considerable overlap between groups.
For example, 12.4% of IBS-only participants reported
37 or more symptoms weekly, showing that some sin-
gle-diagnosis IBS participants report many symptoms.
By contrast, 21.8% of the IBS þ FMS þ CFS partici-
pants reported fewer than 37 symptoms weekly showing
that some of these multiple diagnosis patients have
fewer symptoms than the single-diagnosis IBS partici-
pants. Of those participants with an IBS-only diagnosis,
18.4% had 13 or more symptoms daily whereas 14.7%
of IBS þ FMS þ CFS participants had 12 symptoms or
fewer daily. The mean numbers (SD) of symptoms for
IBS-only, FMS-only, CFS-only, IBS þ CFS,
IBS þ FMS, CFS þ FMS, IBS þ FMS þ CFS groups
on a daily basis were 7.0 (7.4), 16.2 (9.1), 13.3 (7.7),
15.2 (9.9), 19.6 (10.2), 19.0 (8.6) and 23.6 (10.5),
respectively, and those on at least weekly basis were
21.9 (7.0), 35.3 (10.9), 31.6 (10.7), 34.1 (12.7), 41.0
(9.8), 38.1 (9.2), and 43.6 (10.4), respectively; the mean
scale scores (SD) were 2.90 (0.78), 3.81 (0.73), 3.55
(0.70), 3.78 (0.82), 4.21 (0.67), 4.05 (0.61) and 4.42
(0.70), respectively. The standard deviations also show
the wide variation in participants.
Some of the 61 symptoms measured are highly
indicative of either IBS (gastric symptoms), FMS (pain
symptoms), or CFS (fatigue symptoms). In order to
demonstrate to what extent the symptoms used in the
diagnosis of one functional disorder also feature in the
symptomatology of those with a different functional
disorder, Table 2 shows the frequency of these key
symptoms on a daily and at least weekly basis as a
function of the IBS-only, FMS-only, and CFS-only
groups.
In order to provide data on the prevalence of each of
the symptoms, Table 3 provides weekly frequency data
where participants are allocated to three groups, ac-
cording to whether they report an IBS, FMS or CFS
diagnosis, irrespective of whether they reported addi-
tional functional disorder diagnoses. The symptoms are
ordered by the relative frequency of the symptoms in
the sample as a whole. One symptom, “cold sores on or
near lips” fails the criterion for eventual acceptance in
the final symptom questionnaire, but is included in all
analyses for consistency.
The first four unrotated factors of a principle factor
analysis accounted for 35.5%, 4.5%, 3.7% and 2.6% of
Table 2
Frequency (%) of key symptoms at least weekly and daily in the IBS-only, FMS-only and CFS-only groups (n ¼ 900).
Symptoms IBS-only (n ¼ 370) FMS-only (n ¼ 384) CFS-only (n ¼ 146)
Daily Weekly Daily Weekly Daily Weekly
Stomach pain 100 (27.0) 291 (78.6) 40 (10.4) 201 (52.3) 13 (8.9) 62 (42.5)
Diarrhoea 44 (11.9) 250 (67.6) 7 (1.8) 125 (32.6) 3 (2.1) 41 (28.1)
Constipation 31 (8.4) 186 (50.3) 34 (8.9) 197 (51.3) 9 (6.2) 47 (32.2)
Pain increasing the day after you are active 32 (8.6) 119 (32.2) 229 (59.6) 361 (94.0) 57 (39.0) 125 (85.6)
Pain in legs and arms which is not due to hard exercise 39 (10.5) 109 (29.5) 274 (71.4) 364 (94.8) 54 (37.0) 105 (71.9)
Fatigue for no reason 73 (19.7) 230 (62.2) 249 (64.8) 366 (95.3) 114 (78.1) 140 (95.9)
Waking up still feeling tired 134 (36.2) 279 (75.4) 303 (78.9) 372 (96.9) 114 (78.1) 139 (95.2)
IBS: irritable bowel syndrome; FMS: fibromyalgia syndrome; CFS: chronic fatigue syndrome.
Table 1
Frequency (%) of participants reporting different numbers of symptoms on a daily and at least weekly basis (n¼1751).
Number of
symptoms reported
IBS-only
(n ¼ 370)
FMS-only
(n ¼ 384)
CFS-only
(n ¼ 146)
IBS+CFS
(n ¼ 108)
IBS+FMS
(n ¼ 378)
CFS+FMS
(n ¼ 99)
IBS+FMS+CFS
(n ¼ 266)
Daily Weekly Daily Weekly Daily Weekly Daily Weekly Daily Weekly Daily Weekly Daily Weekly
0e6 232 (62.7) 26 (7.0) 58 (15.1) 2 (0.5) 27 (18.5) 1 (0.7) 22 (20.4) 1 (0.9) 34 (9.0) 0 5 (5.1) 0 10 (3.8) 1 (0.4)
7e12 70 (18.9) 53 (17.1) 90 (23.4) 7 (1.8) 51 (34.9) 5 (3.4) 23 (21.3) 6 (5.6) 69 (18.2) 1 (0.3) 17 (17.1) 0 29 (10.9) 1 (0.4)
13e18 35 (9.5) 78 (21.0) 97 (25.3) 22 (5.8) 37 (25.4) 8 (5.5) 27 (25.0) 3 (2.8) 81 (21.5) 5 (1.3) 29 (29.3) 3 (3.0) 52 (19.5) 3 (1.1)
19e24 19 (5.1) 62 (16.8) 69 (18.0) 30 (7.8) 20 (13.7) 24 (16.4) 18 (16.0) 14 (12.9) 78 (20.6) 21 (5.5) 26 (26.3) 4 (4.1) 53 (19.9) 6 (2.2)
25e30 10 (2.7) 56 (15.1) 39 (10.1) 68 (17.7) 5 (3.4) 30 (20.6) 15 (13.9) 20 (18.5) 56 (14.8) 34 (9.0) 13 (13.1) 16 (16.1) 55 (20.7) 21 (7.9)
31e36 0 39 (10.6) 25 (6.5) 76 (19.8) 5 (3.4) 28 (19.2) 1 (0.9) 18 (16.7) 36 (9.6) 55 (14.6) 7 (7.1) 17 (17.2) 30 (11.3) 26 (9.8)
37e42 4 (1.1) 25 (6.7) 5 (1.3) 69 (18.0) 1 (0.7) 27 (18.4) 1 (0.9) 15 (13.9) 18 (4.7) 84 (22.2) 0 24 (24.2) 25 (9.4) 54 (20.3)
43e48 0 13 (3.5) 0 72 (18.7) 0 14 (9.6) 0 16 (14.8) 4 (1.1) 78 (20.6) 1(1.0) 24 (24.2) 11 (4.1) 52 (19.6)
49e54 0 6 (1.7) 1 (0.3) 27 (7.0) 0 8 (5.5) 0 10 (9.3) 1 (0.3) 77 (20.4) 1 (1.0) 8 (8.1) 0 67 (25.1)
55e61 0 2 (0.5) 0 11 (2.9) 0 1 (0.7) 1 (0.9) 5 (4.6) 1 (0.3) 23 (6.1) 0 3 (3.0) 1 (0.4) 35 (13.2)
IBS: irritable bowel syndrome; FMS: fibromyalgia syndrome; CFS: chronic fatigue syndrome.
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Table 3
Number (%) of patients reporting a symptom on at least a weekly basis and factor loadings.a
Item no.Symptom Frequency (%) of symptom reported at least weekly Factor loading on the first unrotated factor
All
(n ¼ 1751)
Any-IBS
(n ¼ 1122)
Any-FMS
(n ¼ 1127)
Any-CFS
(n ¼ 619)
Any-IBS
(n ¼ 1122)
Any-FMS
(n ¼ 1127)
Any-CFS
(n ¼ 619)
13 Waking up still feeling tired 1629 (93.0) 1019 (90.8) 1111 (98.5) 603 (97.4) 0.65 0.41 0.38
10 Fatigue for no reason 1566 (89.5) 961 (85.7) 1095 (97.1) 602 (97.3) 0.73 0.51 0.37
15 Difficulty concentrating 1489 (85.1) 910 (81.1) 1066 (94.6) 587 (94.9) 0.77 0.59 0.57
14 Mental fog 1481 (84.6) 902 (80.5) 1061 (94.1) 583 (94.2) 0.75 0.57 0.54
11 Fatigue increasing the day after
you are active
1471 (84.1) 872 (77.8) 1078 (95.7) 602 (97.3) 0.74 0.48 0.38
16 Memory problems 1455 (83.1) 883 (78.7) 1050 (93.4) 574 (92.7) 0.73 0.52 0.52
38 Waking up often at night 1449 (82.7) 906 (80.7) 1032 (91.6) 521 (84.2) 0.54 0.38 0.44
17 Easily feel too cold 1407 (80.4) 883 (78.7) 984 (87.4) 526 (85.0) 0.52 0.33 0.42
9 Pain increasing the day after
you are active
1398 (79.8) 818 (72.9) 1070 (94.9) 558 (90.2) 0.77 0.48 0.57
23 Bloating of the stomach 1366 (78.0) 970 (86.5) 893 (79.2) 466 (75.3) 0.36 0.50 0.50
2 Pain in legs and arms which is
not due to hard exercise
1357 (77.5) 648 (71.1) 1070 (94.9) 520 (84.0) 0.77 0.48 0.62
7 Back pain 1348 (77.0) 842 (75.1) 1020 (90.6) 486 (78.6) 0.66 0.44 0.56
19 Easily feel too hot/sweating 1340 (76.5) 841 (74.9) 958 (85.0) 510 (82.4) 0.60 0.42 0.47
18 Very cold hands or feet 1339 (76.5) 847 (75.5) 933 (82.8) 499 (80.6) 0.49 0.37 0.45
37 Difficulty getting to sleep 1325 (75.7) 830 (73.9) 957 (84.9) 504 (81.4) 0.62 0.43 0.51
3 Pain moving from one place of
body to another on different days
1268 (72.4) 752 (67) 1022 (90.7) 486 (78.6) 0.76 0.46 0.64
36 Sensitivity to noise 1264 (72.2) 769 (68.5) 937 (83.0) 519 (83.8) 0.72 0.58 0.60
5 Stomach pain 1233 (70.4) 910 (81.1) 799 (70.9) 421 (68.0) 0.38 0.60 0.57
8 Sensitive or tender skin 1229 (70.2) 750 (66.8) 969 (86.0) 447 (72.2) 0.70 0.49 0.64
29 Irritable 1220 (69.6) 786 (70.0) 860 (76.2) 434 (70.1) 0.57 0.54 0.53
35 Sensitivity to bright lights 1178 (67.2) 718 (64.0) 888 (78.8) 487 (83.8) 0.73 0.59 0.60
30 Jittery, easily startled, often worried 1175 (67.1) 765 (68.2) 840 (74.5) 423 (68.4) 0.61 0.58 0.58
34 More clumsy than others 1161 (66.3) 713 (63.5) 869 (77.0) 482 (77.8) 0.70 0.58 0.57
20 Thirsty all the time 1154 (65.9) 736 (65.5) 865 (76.7) 440 (71.1) 0.61 0.45 0.51
56 Numbness, tingling, pins and needles1153 (65.9) 703 (62.7) 894 (79.3) 446 (72.1) 0.76 0.58 0.68
4 Headaches 1149 (65.6) 722 (64.3) 588 (74.5) 453 (73.2) 0.59 0.50 0.52
28 Feeling anxious for no reason 1125 (64.3) 743 (66.2) 793 (70.4) 395 (63.8) 0.54 0.53 0.52
44 Itchy skin 1122 (64.1) 735 (65.5) 836 (74.2) 421 (68.0) 0.61 0.53 0.60
26 Intolerant to some food 1082 (61.8) 806 (71.8) 655 (58.1) 406 (65.6) 0.21 0.36 0.34
45 Itchy eyes 1013 (57.8) 664 (59.2) 756 (67.1) 388 (62.7) 0.58 0.53 0.61
22 Constipation 1002 (57.2) 709 (63.2) 710 (63.0) 347 (56.1) 0.37 0.37 0.41
59 Feeling out of breath for no reason 989 (56.4) 628 (56.0) 739 (65.6) 432 (69.8) 0.70 0.63 0.56
39 Racing heart 959 (54.8) 608 (54.2) 688 (61.0) 391 (63.2) 0.61 0.57 0.49
1 Swollen painful joints 953 (54.5) 582 (51.9) 766 (68.0) 355 (57.4) 0.59 0.38 0.54
55 Cramps in leg, foot or bottom 947 (54.1) 601 (53.5) 743 (65.9) 357 (57.6) 0.68 0.59 0.66
32 Very vivid dreams 944 (53.9) 608 (54.3) 656 (58.2) 381 (61.5) 0.47 0.46 0.45
61 Feeling very ill for no reason 937 (53.4) 579 (51.6) 689 (61.2) 446 (51.0) 0.73 0.62 0.52
27 Depression 920 (52.6) 603 (53.8) 690 (61.2) 330 (53.4) 0.55 0.48 0.50
25 Nausea for no reason 917 (52.4) 619 (55.1) 625 (55.5) 376 (60.7) 0.57 0.60 0.56
12 Fatigue increasing after a cold
or sore throat
910 (52.0) 558 (49.8) 691 (61.3) 396 (64.0) 0.61 0.42 0.37
21 Diarrhoea 874 (49.9) 684 (61.0) 518 (45.9) 281 (45.4) 0.09 0.38 0.34
42 Blocked nose 871 (49.7) 575 (51.3) 651 (57.8) 336 (54.3) 0.48 0.42 0.43
58 Urinating two or more times
per night
854 (48.8) 563 (50.1) 639 (56.7) 330 (53.3) 0.46 0.41 0.46
41 Face flushes 848 (48.4) 536 (47.7) 638 (56.7) 314 (50.8) 0.54 0.44 0.51
40 Hands tremble or shake 838 (47.8) 529 (47.2) 655 (58.1) 349 (56.4) 0.69 0.63 0.59
31 Ringing in ears 823 (47.1) 518 (46.2) 603 (53.5) 347 (56.1) 0.45 0.37 0.41
24 Heartburn 819 (46.8) 569 (50.7) 579 (79.2) 272 (43.9) 0.39 0.39 0.44
43 Running nose 786 (44.9) 533 (47.5) 572 (50.8) 296 (47.8) 0.42 0.40 0.40
(continued on next page)
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Table 3 (continued )
Item no.Symptom Frequency (%) of symptom reported at least weekly Factor loading on the first unrotated factor
All
(n ¼ 1751)
Any-IBS
(n ¼ 1122)
Any-FMS
(n ¼ 1127)
Any-CFS
(n ¼ 619)
Any-IBS
(n ¼ 1122)
Any-FMS
(n ¼ 1127)
Any-CFS
(n ¼ 619)
6 Chest pain 733 (41.8) 475 (42.3) 577 (51.2) 293 (47.4) 0.64 0.57 0.55
54 Feeling faint 658 (37.6) 419 (37.4) 461 (40.9) 333 (53.8) 0.62 0.60 0.52
52 Twitching other than eyelid 558 (31.9) 349 (31.1) 459 (40.7) 265 (42.8) 0.64 0.54 0.56
51 Twitching of eyelid 546 (31.3) 348 (31.0) 434 (38.4) 238 (38.4) 0.61 0.55 0.55
33 Nightmares/night terrors 480 (27.4) 316 (28.2) 353 (31.2) 206 (33.2) 0.53 0.52 0.55
60 Double vision 469 (26.8) 297 (26.6) 372 (33.0) 233 (37.7) 0.59 0.52 0.55
50 Boils or pimples on face or body 448 (25.6) 294 (26.3) 309 (27.4) 196 (31.7) 0.37 0.35 0.34
53 Choking sensations 409 (23.4) 291 (25.9) 413 (29.7) 169 (27.3) 0.58 0.53 0.57
49 Skin rash 365 (20.8) 252 (22.5) 266 (23.6) 146 (23.6) 0.44 0.41 0.41
46 Head colds, sore throat, flu 353 (20.2) 234 (20.9) 260 (23.0) 191 (30.9) 0.52 0.50 0.49
47 Mouth ulcers, sores in mouth 268 (15.3) 177 (15.8) 214 (19.0) 108 (17.5) 0.43 0.41 0.42
57 Loss of voice 259 (14.8) 177 (15.8) 214 (19.0) 113 (18.3) 0.49 0.41 0.40
48 Cold sores on or near lips 79 (4.5) 54 (4.8) 65 (5.8) 34 (5.4) 0.34 0.30 0.33
IBS: irritable bowel syndrome; FMS: fibromyalgia syndrome; CFS: chronic fatigue syndrome.
a The groups refer to participants reporting a diagnosis of IBS, FMS and CFS, irrespective of whether the participant reports other additional
functional disorders.
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25.0%, 4.8%, 3.4% and 3.0% of the variance respec-
tively for the any-FMS and 26.7%, 5.0%, 3.9%, and
3.1% of the variance respectively for the any-CFS
group, the scree test indicating a one-factor solution.
Table 3 provides the factor loadings of the first unro-
tated factor for the three groups. All except one
symptom load >0.3 for each of the three groups on the
first unrotated factor. Cronbach's alpha for the total
population was 0.96.
The number of factors with eigenvalues above 1.0
was 12 for the any-IBS group, 15 for the any-FMS
group, and 14 for the any-CFS groups. A principal
axis factor analysis with extraction set for 12 factors and
oblimin rotation was carried out for each of the three
groups, factor loadings of equal to or above 0.3 were
deemed significant, and the pattern matrices of the three
factor analyses were compared. For each of the three
analyses, at least one third of factor inter-correlations
were at or above 0.3 and 17%e40% were below 0.2
(Tables S4-S6 in the Supplementary Appendix).
Tables S7-S9 in the Supplementary Appendix pro-
vides the pattern matrices for the three factor analyses.
Discounting the factor number, some groups of items
loaded on only one factor for all three groups. These
consistent factors comprised (a) mood (depression;
feeling anxious for no reason; irritable; jittery, easily
startled, often worried), (b) stimulus sensitivity (sensi-
tivity to noise; sensitivity to bright lights), (c) dreams
(very vivid dreams; nightmares, night terrors), (d) cold
(easily feel too cold; very cold hands and feet), and (e)
atopy (blocked nose; running nose; itchy skin; itchyeyes). The three cognitive symptoms (mental fog;
memory problems; difficulty concentrating) loaded on
only one factor for all groups, but the symptom “waking
up still feeling tired” also loaded on this factor (and only
this factor) for the any-IBS group. The neurological
symptoms (hands tremble or shake; twitching of eyelid;
twitching other than eyelid; feeling faint and numbness;
double vision) loaded on the same factor for all groups.
Five gastric symptoms (stomach pain, heartburn, bloat-
ing, nausea, food intolerance) loaded on a single factor
for all groups with diarrhoea additionally loading for
any-CFS and any-FMS though constipation failed to
load for any of the groups. Two skin symptoms (skin
rash, boils or pimples on face or body) loaded on a single
factor for all groups, but with additional skin-related
items loading for some groups. The two sleep items
(difficulty getting to sleep, waking up often at night)
loaded on the same factor for the any-FMS and any-IBS
groups but not the any-CFS group where they failed to
load. The pain symptoms (excluding stomach pain but
including sensitive or tender skin) and fatigue symptoms
loaded on separate factors for the any-FMS and any-CFS
groups but both types of symptoms (with the exception
of waking up still feeling tired) loaded on one factor for
the any-IBS group. There was only one instance of a
cross-loading item in all three analyses: itchy skin loaded
on atopy and skin symptoms factor for the IBS-any
group. Seven symptoms (headaches, easily feel too hot,
thirsty all the time, constipation, ringing in ears, face
flushes, loss of voice) failed to load on any of the 12
factors for any of the three analyses, though all seven
loaded on the first unrotated factor.
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were searched for frequently occurring symptoms not
included in the 61-symptom questionnaire. Obvious
synonyms were discounted. Of the 1751 patients, 52
reported urination problems such as urgency, fre-
quency, pain or hesitation, 48 referred to balance
problems of one kind or another, 47 reported restless
legs, 40 reported hair loss, brittle hair or hair thinning,
34 patients referred to dizziness and 22 participants
referred to blurred vision (in contrast to double vision).
Discussion
There were two related aims for this study: first, to
examine the evidence for a generic functional disorder
symptom scale, and second to produce such a scale.
One reason for using a generic scale is because of high
comorbidity between functional disorders. In this
internet study of participants recruited through IBS,
FMS and CFS websites, 49% reported being diagnosed
with more than one functional disorder.8,9 However,
even where participants report a single diagnosis,
symptoms associated with other diagnoses are com-
mon. Inspection of Table 2 shows that stomach pain is
reported by 78.6% of those in the IBS-only group,
52.3% of the FMS-only group and 42.5% of the CFS-
only group on a weekly basis. Although stomach pain
is less frequent in those lacking an IBS diagnosis, it is
sufficiently common for it be a relevant symptom for
symptom assessment. Furthermore, the frequency that
IBS-only participants report stomach pain is similar to
the frequency that the IBS-only participants experience
waking still feeling tired, and that the frequency of
constipation in the FMS-only group is similar to the
frequency of those in the IBS-only group.
The scree test indicates a unifactorial solution. The
first unrotated factor of a factor analysis of symptoms
is a severity factor. The finding that all (with one
exception) symptoms loaded on the first factor for the
any-IBS, any-FMS and any-CFS analyses demon-
strates the wide variety of symptoms that can occur in
functional disorders and shows that all symptoms co-
vary with severity and are therefore likely to have some
form of common cause.
Severity, as measured by the number of symptoms
reported by patients increases with the number of di-
agnoses but participants were polysymptomatic irre-
spective of functional disorder diagnosis. IBS-only
patients reported the fewest number of symptoms, with
a mean weekly symptom number of 21.9, and
IBS þ FMS þ CFS the most with a mean weekly
symptom number of 43.6, but there was considerableoverlap between the seven groups, and the standard
deviations for the weekly and daily symptom number
and scale score are all comparatively high. Variation in
severity as measured by a wide spectrum of symptoms
is therefore an important feature of functional disorders
independently of diagnosis.
The results from the factor analysis are consistent
with previous research, namely an over-arching com-
mon factor accounting for about one third of the var-
iance,23e25 below which are several inter-correlated
specific factors.15,26 The finding that the first factor
accounted for between five and seven times the vari-
ance of the second unrotated factor shows that the
relative contribution of the specific factors is compar-
atively small when compared to the higher order factor.
Additionally, although 12 factors were identified, this
is likely to be an underestimation of the number of
different specific factors that are subsumed within the
higher order factor. Finally, it should be noted that the
present finding that constipation did not load with
diarrhoea in the 12 factor solution is replicated else-
where,17 which suggests that diarrhoea and con-
stipation may have different specific mechanisms, and
the failure of constipation to load on the higher order
factor may be due to the importance of a specific
mechanism for this symptom.
A difference between this study and previous
studies is that the sample size was sufficiently large to
replicate the results of factor analysis with different
groups. Although loadings on the 12 factor solution
were not identical between the any-IBS, any-FMS and
any-CFS groups, they were sufficiently similar to
conclude that the factor structure, including the pro-
portion of variance explained by the higher-order,
common factor, was the same for all three groups,
thereby demonstrating the validity of the same generic
symptoms scale being used in patients having either an
IBS, FMS or CFS diagnosis.
The frequency with which symptoms were reported
provides an objective criterion for inclusion in the final
questionnaire. Only one symptom (“cold sores on or
near lips”) failed the criterion of weekly prevalence of
10% and therefore should be excluded from the final
questionnaire. Two other symptoms were infrequent
with prevalence of about 15% in the total population,
but they should not be excluded as they have a preva-
lence of 19.0% in the FMS group. “Waking up still
feeling tired” was the most prevalent symptom; in-
spection of the frequency of this symptom in Tables 2
and 3 provides evidence of a ceiling effect, but this
symptom had acceptable factor loadings for all groups.
Note that the higher factor loading in the any-IBS group
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tom may be more sensitive to change and more
discriminating in IBS patients as there is less attenuation
of range in milder patients with more frequent symp-
toms. Table 3 shows considerable variation in the fre-
quency of symptoms, which is needed if the scale is to
be sensitive to change over the full range of severities.
Participants were asked to identify symptoms not on
the original list, and although some of these were
versions of symptoms already present, there is evi-
dence that five additional symptoms could be added,
namely, restless legs, hair loss/brittle hair/thinning,
dizziness/balance problems, blurred vision and urina-
tion problems. Note that three free text reporting of
symptoms would underestimate the frequency when
solicited by an item in a questionnaire.
Combining the data from Table 3 with the freely eli-
cited symptoms, a comprehensive, 65-item generic
symptom questionnaire (the GSQ-65 in the
Supplementary Appendix) can be constructed from data
reported here (i.e., the original 61, less one plus five new
ones obtained from free text responses).
Three methods of scoring the questionnaire were
considered: weekly symptoms, daily symptoms and the
scale score. Of these methods, the scale score was the
best discriminator between the seven different diag-
nostic categories (i.e., had the highest F value) closely
followed by the number of symptoms experienced
weekly or more often. The number of daily symptoms
was a poorer discriminator. These results show that the
scale score is the optimum scoring method, but the
number of symptoms experienced on a weekly basis or
more is an acceptable alternative.
The limitation of this study lies in the fact that the
sample is predominantly female. The prevalence of
females is greater for functional disorders than males,
but the predominance of females in our sample may
reflect a greater willingness of women to complete
health related questionnaires. The duration of time
since diagnosis of participants is unknown.
Functional disorders are spectrum disorders.
Although specific symptom scales are useful for
measuring the defining features of IBS, FMS or CFS,
there is such an overlap in symptoms that a generic
symptom questionnaire is required for a comprehen-
sive measure of the symptomatology of people with
any of these three diagnoses or, more generally, people
given the diagnostic label of “bodily distress syn-
drome”.27 However, care must be taken in the words
chosen to describe patients with functional disorders as
some labels are known to offend.28Many of the symptom descriptors in the GSQ-65 are
common to other scales, but some are unique to this
scale due to the patient-derived method of symptom
wording and method of symptom selection. For
example, the comprehensive rating scale for fibromy-
algia symptomatology (CRSFS)26 is a well-constructed
60-symptom questionnaire based on focus groups of
FMS patients. However, this scale does not include the
symptoms of diarrhoea, constipation or stomach pain,
nor the symptom of feeling cold, both of which are
shown in this study to be common in FMS. A likely
reason for this omission is that FMS patients did not
perceive IBS-complaints and being cold as being due
to FMS. Similarly, the COMPASS questionnaire, in
both long and short formats16,17 does include IBS-
related symptoms but does not include symptoms
relating to cognitive dysfunction. The CRSFS includes
several cognitive dysfunction symptoms as does the
GSQ-65 (there are fewer in the GSQ-65), and the
present data show this to be a comparatively frequent
type of symptom. In this study the procedure for
identifying symptoms meant that symptoms were not
selected on the basis of perceptions of diagnosis (as in
the case of the CRSFS) or perceived cause (as in the
case of the COMPASS). The GSQ-65 is more heter-
ogenous than other scales, and therefore more suited
when the aim is to assess a wide range of symptoms.
In sum, the GSQ-65 is a valid, generic functional
disorder scale. Sensitivity to change and retest reli-
ability are yet to be determined.
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